Phage display and molecular imaging: expanding fields of vision in living subjects

Abstract

In vivo molecular imaging enables non-invasive visualization of biological processes within living subjects, and holds great promise for diagnosis and monitoring of disease. The ability to create new agents that bind to molecular targets and deliver imaging probes to desired locations in the body is critically important to further advance this field. To address this need, phage display, an established technology for the discovery and development of novel binding agents, is increasingly becoming a key component of many molecular imaging research programs. This review discusses the expanding role played by phage display in the field of molecular imaging with a focus on in vivo applications. Furthermore, new methodological advances in phage display that can be directly applied to the discovery and development of molecular imaging agents are described. Various phage library selection strategies are summarized and compared, including selections against purified target, intact cells, and ex vivo tissue, plus in vivo homing strategies. An outline of the process for converting polypeptides obtained from phage display library selections into successful in vivo imaging agents is provided, including strategies to optimize in vivo performance. Additionally, the use selections are performed against pre-defined targets, the use of cell lines, tissue, and in vivo homing selections have also been valuable. These latter strategies avoid the need to identify a specific target at the outset, allow library selections under conditions potentially more relevant to a clinical setting, and can lead to the discovery of unanticipated and interesting targets. The full potential of phage display is far from being completely explored; many library formats and selection strategies have not been fully exploited for the production of molecular imaging agents. The successful and rapid translation of phage-derived molecular imaging agents into the clinic remains a challenge, but new methods and tools are becoming available for optimizing in vivo performance. In conclusion, phage display will continue to be a significant driving force and a key player in enabling in vivo molecular imaging to deliver on its promise for both basic science and clinical applications.